According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan ...According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.展开更多
Regulatory status of drug inserts in China is described in terms of its legalsystem, administrative ramifications and existing problems. Lack of government regulatoryenforcement, industry self-control mechanisms and a...Regulatory status of drug inserts in China is described in terms of its legalsystem, administrative ramifications and existing problems. Lack of government regulatoryenforcement, industry self-control mechanisms and academic research are blamed to be the root ofthese problems. The trend of regulatory policies on the issue is outlined and suggestions on severalimportant issues are made.展开更多
Based on the xu-argument, this study investigated the use of translation continuation tasks in commercial translation instruction. Forty-four second-year Business English majors at a Chinese university participated in...Based on the xu-argument, this study investigated the use of translation continuation tasks in commercial translation instruction. Forty-four second-year Business English majors at a Chinese university participated in the study. They were divided into equal-sized control and experimental groups. Members of the experimental group were asked to read Chinese-English parallel texts from a user manual, while those of the control group were asked to read the Chinese text only.Subsequently, both groups were required to translate the continued Chinese text into English. The results indicated the following: 1) the experimental group’s translated text was of significantly higher quality than that of the control group;and 2) the experimental group’s translations were well-aligned with the original text in their use of terminology, sentence structure, and stylistic features. The study concludes by suggesting that translation continuation tasks can improve commercial translation instruction and hence should be further applied in practice.展开更多
文摘According to the drug-related risk factors indicated in the latest product monograph, we made this research to analyze and discuss the risk factors associated with rosiglitazone in clinical application in China-Japan Friendship Hospital. We collected and reviewed all cases involving inpatients who had used rosiglitazone in the hospital over the past two years. The focus of our study is on the identification and discussion of the incidence of adverse reactions, contraindications and drug induced problems associ- ated with monotherapy or combined therapy of rosiglitazone. Three hundred and ninety eight cases were reviewed in the study including 3 patients with type 1 DM （0.75%） and 395 patients with type 2 diabetes mellitus （99.25%）. Peripheral edema developed in 9 patients （2.26%） in the course of rosiglitazone therapy; one patient （0.25%） was found to have macula edema before rosiglitazone therapy; Cardiac abnormalities were identified in 6 patients （1.51%） in the course of treatment, of which 2 patients were NYHA class 1, 3 patients were NYHA class Ⅱ and 1 patient was NYHA class IV. Abnormal hepatic function （elevated ALT） was found in 79 patients （19.85%） during their stay in hospital. In these patients, ALT levels of 1 - 2.5 times, 2.5 - 3 times over the upper limit were identified in 70 patients, 3 patients and 6 patients, respectively. Of the 398 patients on rosiglitazone, 123 patients （30.90%）, 165 patients （41.46%）, 104 patients （26.13%）, 3 patients （0.75%） and 1 patient （0.25%） were found to use concurrently insulin, metformin, organic nitrate, gemfibrozil and rifampin, respectively. We analyzed the risk factors associated with the clinical use of rosiglitazone, and identified the potential risks, and put forward suggestions to improve the effectiveness and safety of rosiglitazone therapy.
文摘Regulatory status of drug inserts in China is described in terms of its legalsystem, administrative ramifications and existing problems. Lack of government regulatoryenforcement, industry self-control mechanisms and academic research are blamed to be the root ofthese problems. The trend of regulatory policies on the issue is outlined and suggestions on severalimportant issues are made.
文摘Based on the xu-argument, this study investigated the use of translation continuation tasks in commercial translation instruction. Forty-four second-year Business English majors at a Chinese university participated in the study. They were divided into equal-sized control and experimental groups. Members of the experimental group were asked to read Chinese-English parallel texts from a user manual, while those of the control group were asked to read the Chinese text only.Subsequently, both groups were required to translate the continued Chinese text into English. The results indicated the following: 1) the experimental group’s translated text was of significantly higher quality than that of the control group;and 2) the experimental group’s translations were well-aligned with the original text in their use of terminology, sentence structure, and stylistic features. The study concludes by suggesting that translation continuation tasks can improve commercial translation instruction and hence should be further applied in practice.
